Business Intelligence Group Names BostonGene Outstanding Organization and Double Winner in the 2026 Artificial Intelligence Excellence Awards
Honors Recognize BostonGene's Platforms for Accelerating Trial Design, Improving Patient Selection and De-Risking Precision Medicine Outcomes at Scale
BostonGene, developer of the leading AI model for tumor and immune biology, today announced that it has been recognized as the Overall Winner in the 2026 Artificial Intelligence Excellence Awards by the Business Intelligence Group. The global program named BostonGene an Outstanding Organization, while simultaneously awarding top product honors for its multimodal AI platform.
By integrating genomic, transcriptomic, immune profiling, imaging, and clinical data into unified biological models, BostonGene helps biopharma organizations improve patient selection, identify predictive biomarkers, understand mechanisms of response and resistance, and make more informed development decisions. This recognition highlights BostonGene's ability to transform complex biological data into actionable insights that improve both clinical and business outcomes.
In active development programs conducted with global pharmaceutical partners, BostonGene has helped accelerate translational research, strengthen biomarker strategies, and support more confident decision-making across the R&D lifecycle.
